跳至主要内容
临床试验/NCT03970434
NCT03970434已完成1 期

Clinical Trial to Evaluate Drug Concentration of Metformin According to Sampling Method in Healthy Adult Volunteers

Chonbuk National University Hospital2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2019年5月30日最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
入组人数
20
试验地点
2
主要终点
Concentration of Metformin

研究概览

简要总结

This study assess the drug concentration of metformin in healthy adult volunteers according to the sampling method.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy male subjects who, at the time of screening, are the age of older than 19 years
  • Subjects who have BMI more than 17.5kg/m2 and less than 30.5kg/m2 and body weight more than 55kg
  • There is no congenital disease or within 3 years of chronic diseases
  • Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, ECG or clinical laboratory tests
  • Subjects who signed and dated the informed consent form(approved by IRB) after understanding fully to hear a detailed explanation in the clinical trial

排除标准

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease
  • A subject with any history of gastrointestinal disease (e.g., Crohn's disease, acute or chronic pancreatitis, and others) and surgery (except for simple appendectomy or repair of a hernia), which can influence the absorption of investigational products
  • A subject who has the following clinical laboratory test results Liver Function Test (AST, ALT) > two times the upper limit of the normal range
  • History of regular alcohol consumption exceeding 210g/week(12g = 125 mL of wine, 10g = 250 mL of beer, 10g = 50 mL of hard liquor) within 6 months of Screening
  • A subject who has participated in any other clinical trials and had medication within 3 months prior to the first administration of investigational product.
  • A subject with a history of drug abuse or a positive urine drug screening for drug abuse within 1 year
  • A subject who has taken the drugs that induce and suppress drug- metabolizing enzymes within 30 days prior to investigational product administration
  • A smoker who consumes more than 20 cigarettes/day within 6 months
  • A subject who has taken any ethical-the-counter drug or has taken any over- the-counter drug within 10 days before the investigational product administration
  • A subject who has donated whole blood within 2 months or blood components within 1 month prior to the investigational product administration
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation

研究组 & 干预措施

Metformin

Experimental

干预措施: Peripheral blood collection (Other)

Metformin

Experimental

干预措施: Venous blood collection (Other)

结局指标

主要结局

Concentration of Metformin

时间窗: 10 hours

Compare the concentration of Metformin measured from Venous blood collection and Peripheral blood collection.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Min-Gul Kim, MD, PhD

Center for Clinical Pharmacology

Chonbuk National University Hospital

研究点 (2)

Loading locations...

相似试验